Additionally, the safety and potential interactions of high-dose antioxidants with other medications pose challenges in tailoring antioxidant therapy for specific individuals
Although its often spoken about as one thing, its consequences look different depending on the organ system involved: Metabolic organs (liver, adipose tissue, pancreas): Chronic inflammation here is associated with insulin resistance, higher glucose, and fatty liver disease. Blood vessels / cardiometabolic system: Inflammation contributes to long-term cardiovascular risk, and GLP-1 therapies improve several cardiometabolic risk factors, including blood pressure. Kidneys: Metabolic stress accelerates kidney damage and albuminuria
And how do GLP-1 medications, such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro) or retridae ,dampen it
Moderate appetite pathway engagement compared to GHRP-6: Although GHRP-2 activates the same ghrelin receptor as GHRP-6, appetite stimulation tends to be less pronounced
Wajdlich, M
GLP-1 receptor agonist market